Ekspresi Imunohistokimia Human Epididymis Protein 4 Pada Jaringan Kista Ovarium Benigna
DAFTAR PUSTAKA
1. Frequently Asked Question FAQ075 Gynecologic Problem. The
American College of Obstetricians and Gynecologists. July 2015
2. Grabosch SM, Karjane NW. Ovarian Cysts. January 2017. Available at:
http://emedicine.medscape.com/article/255865-overview
3. Kaloo PD et al. Management of Suspected Ovarian Masses in
Premenopausal Women. Royal College of Obstetricians and
Gynaecologists Green-top Guideline No. 62. November 2011.p1-14
4. Modesitt SC, Pavlik EJ, Ueland FR, et al. Risk of malignancy in unicolar
ovarian cystic tumors less than 10 centimeters in diameter. Obstet
Gynecol. 2003; 102:594-599
5. Dorum A, Blom GP, Ekerhovd E, et al. Prevalence and histologic
diagnosis of adnexal cysts in postmenopausal women: an autopsy study.
Am J Obstet Gynecol. 2005; 192:48-54
6. Myers ER, Bastian LA, Havrilesky LJ, et al. Management of adnexal
mass. Evid Rep Technol Assess, 2006; 130:1-145
7. Knudsen UB, Tabor A, Mosgaard B, et al. Management of ovarian cysts.
Acta Obstet Gynecol Scand. 2004;83:1012-1021
8. Royal College of Obstetricians and Gynecologists. Ovarian cysts in
postmenopauseal women. October 2003. http://www.rcog.org.uk
9. National Cancer Institute. SEER cancer statistics review, 1975-2003.
http://seer.cancer.gov
10. Grabosch SM, Karjane NW. Ovarian Cysts. Jan 2017. Available at:
http://emedicine.medscape.com/article/255865-overview
11. Kim KA, et al. Benign Ovarian Tumors with Solid and Cystic Components
That Mimic Malignancy. American Journal of Roentgenology.
2004 182:5, 1259-1265
12. Hamed et al. Diagnostic Pathology 2013, 8:11. Available at :
http://www.diagnosticpathology.org/content/8/1/11
13. Karlsen NS, Karlsen MA, Høgdall CK, Høgdall EVS. HE4 Tissue
Expression and Serum HE4 Levels in Healthy Individuals and Patients
with Benign or Malignant Tumors: A Systematic Review. Cancer
Epidemiol Biomarkers Prev; 23(11) November 2014
Universitas Sumatera Utara
14. Zhu L et al. Overexpression of HE4 (human epididymis protein 4)
enhances proliferation, invasion and metastasis of ovarian cancer.
Oncotarget,
Vol.
7,
No.
1.
2015.
Available
at:
www.impactjournals.com/oncotarget/
15. Jinping Li. HE4 (WFDC2) Promotes Tumor Growth in Endometrial
Cancer Cell Lines. Int. J. Mol. Sci. 2013, 14, 6026-6043;
doi:10.3390/ijms14036026
16. Zhuang H, Gao J, Hu Z, Liu J, Liu D, et al. (2013) Co-Expression of
Lewis y Antigen with Human epididymis protein 4 in Ovarian Epithelial
Carcinoma. PLoS ONE 8(7): e68994. doi:10.1371/journal.pone.0068994
17. Moore, R.G. et al. HE4 (WFDC2) gene overexpression promotes ovarian
tumor growth. Sci. Rep. 4, 3574 (2014).
18. Drapkin R. Human epididymis protein 4 (HE4) Is a Secreted Glycoprotein
that Is Overexpressed by Serous and Endometrioid Ovarian Carcinomas.
Cancer Res 2005; 65: (6). March 15, 2005
19. Mayo clinic staff. Ovarian cyst. Available at: www.mayoclinic.org
20. Nordqvist C. Ovarian Cysts: Causes, Symptoms and Treatments. 2015.
Available at: http://www.medicalnewstoday.com
21. Suryati, Gambaran kejadian kista ovarium pada wanita usia Di rumah
sakit khusus daerah ibu dan anak Pertiwi makassar tahun 2014,
Universitas Indonesia Timur, Makassar, 2015
22. Safitri, Y., Pengalaman Wanita Usia Subur Dengan Kista Ovarium,
Departemen Epidemiologi, Fakultas Kesehatan Masyarakat, Universitas
Sumatera Utara, 2010.
23. Siringo D., Hiswani, Jemadi, Karakteristik penderita kista ovarium yang
dirawat inap di Rumah Sakit St Elizabeth Medan tahun 2008-2012,
Departemen Epidemiologi, Fakultas Kesehatan Masyarakat-Universitas
Sumatera Utara, 2012.
24. Parazzini F, Moroni S, Negri E, La Vecchia C, Dal Pino D, Ricci E. Risk
factors for functional ovarian cysts. Epidemiology. 1996 Sep;7(5):547-9.
25. Wiknjosastro, H. Tumor jinak pada alat genital, dalam Ilmu Kandungan,
Yayasan Bina Pustaka Sarwono Prawirohardjo, Jakarta, 2005, Hal :
355-62
26. Mansjoer, dkk., Kapita Selekta Kedokteran edisi ketiga jilid 1, Media
Aesculapius, Jakarta, 2000
Universitas Sumatera Utara
27. Choi, J.-H., Ovarian Epithelial Cancer: Etiology and Pathogenesis.
BioWave, vol. 10. 2008
28. Llewellyn, dkk., Dasar-dasar Obstetri dan Ginekologi, Hipokrates, ,
Jakarta, 2001
29. Auersperg, N., Wong, A. S. T., Choi, K.-C., Kang, S. K. & Leung, P. C. K,
Ovarian surface epithelium, in biology, endocrinology, and pathology.
Endocrine Reviews, volume 22, 2001, page: 255-88.
30. Denny L et al. Staging classification and clinical practice guidelines for
gynaecologic cancers. FIGO Committee on Gynecologic Oncology,
2009.
31. Brohet RM, Goldgar DE, Easton DF, et al. Oral contraceptives and
breast cancer risk in the international BRCA1/2 carrier cohort study: a
report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS
collaborating group. J Clin Oncol.2007;25:3831-6
32. WHO, GLOBOCAN, International agency of research and cancer 2008
33. Bustam M., Epidemiologi Penyakit Tidak Menular, Penerbit Rineka Cipta,
Jakarta, 2007.
34. du Bois A, Rochon J, Pfisterer J, Hoskins WJ. Variations in institutional
infrastructure, physician specialization and experience, and outcome in
ovarian cancer: a systematic review. Gynecol Oncol.2009;112:422-36.
35. Manuaba,I.B.C., & Manuaba, I.B.G., Buku Ajar Penuntun Kuliah
Ginekologi, Penerbit CV. Trans Ino Media, Jakarta, 2010
36. William H., C..2007. American College of Obstetricians and
Gynecologists Ovarian Cysts. http://emedicine.com diakses tanggal 24
Januari 2017
37. Robboy's, Pathology of The Female Reproductive Tract, Elsevier, 2009
38. Stanford JL. Oral contraceptives and
Contraception. 1991 Jun;43(6):543-56.
neoplasia
of
the
ovary.
39. Vessey M, Metcalfe A, Wells C, McPherson K, Westhoff C, Yeates D.
Ovarian neoplasms, functional ovarian cysts, and oral contraceptives. Br
Med J (Clin Res Ed). 1987 Jun 13;294(6586):1518-20.
Universitas Sumatera Utara
40. Henderson,C., Kista Ovarium, dalam Buku Ajar Konsep Kebidanan,
EGC, Jakarta, 2005
41. Rostgaard K. Does pregnancy induce the shedding of premalignat
ovarian cells? Epidemiology.2003;14:168
42. Whittermore AS. Characteristic relating to ovarian cancer risk,
Collaborating ovarian cancer group. Am J Epidemiol.1992;136:11841203
43. Kumar, V., Abbas, A.K., Fausto, N. & Aster, J.C., Robbins & Cotran,
Ovarian Cyst, in Pathologic Basis of Diseases. 2010
44. Kurman RJ, Shih le-Ming. Pathogenesis of ovarian cancer: lessons from
morphology and molecular biology and their clinical implications. Int J
Gynecol Pathol. 2008;27(2):151-60
45. Barber HR, Graber EA. The PMPO syndrome (postmenopausal palpable
ovary syndrome). Obstet Gynecol 1971;38:921–3.
46. Kahraman K, Ozguven I, Gungor M, Atabekoglu CS. Extremely elevated
serum CA-125 level as a result of unruptured unilateral endometrioma:
the highest value reported. Fertil Steril 2007;88:15–7.
47. Van Calster B, Timmerman D, Bourne T, Testa AC, Van Holsbeke C,
Domali E, et al. Discrimination between benign and malignant adnexal
masses by specialist ultrasound examination versus serum CA-125. J
Natl Cancer Inst 2007;99:1706–14.
48. McLemore MR, Aouizerat BE, Lee KA, Chen LM, Cooper B, Tozzi M. A
comparison of the cyclic variation in serum levels of CA-125 across the
menstrual cycle using two commercial assays. Biol Res Nurs
2012;14:250–6.
49. Hamed EO, Ahmed H, Sedeek OB, Mohammed AM, Abd-Alla AA, Abdel
Ghaffar HM. Significance of HE4 estimation in comparison with CA-125
in diagnosis of ovarian cancer and assessment of treatment response.
Diagn Pathol 2013;23:8–11.
50. Demir RH, Marchand GJ. Adnexal masses suspected to Be benign
treated with laparoscopy. JSLS 2012;16:71–84.
51. Timmerman D, Ameye L, Fischerova D, Epstein E,Melis GB, Guerriero
S, et al. Simple ultrasound rules to distinguish between benign and
malignant adnexal masses before surgery: prospective validation by
IOTA
group.
BMJ
2010;14(341):c6839.
http://dx.doi.org/10.1136/bmj.c6839.
Universitas Sumatera Utara
52. Cramer DW, Bast Jr RC, Berg CD, Diamandis EP, Godwin AK, Hartge P,
et al. Ovarian cancer biomarker performance in prostate, lung, colorectal,
and ovarian cancer screening trial specimens. Cancer Prev Res
2011;4:365–74.
53. Ferraro S, Braga F, Lanzoni M, Boracchi P, Biganzoli EM, Panteghini M.
Serum human epididymis protein 4 vs carbohydrate antigen 125 for
ovarian cancer diagnosis: a systematic review. Journal of clinical
pathology. 2013;66(4):273-81.
54. Hussain, F. Gynecologic Tumor Markers Overview [Internet]. Medscape;
1 August 2012, cited 19 November 2014. Available at:
http://emedicine.medscape.com/article/269839-overview#showall.
55. Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk
of malignancy index incorporating CA-125, ultrasound and menopausal
status for the accurate preoperative diagnosis of ovarian cancer. Br J
Obstet Gynecolo. 1990; 97:922-9
56. Granato T, Porpora MG, Longo F, Angeloni A, Manganaro L, Anastasi E.
HE4 in the differential diagnosis of ovarian masses. Clinica Chimica Acta
446 (2015) 147–155
57. Vucetic Z. Risk of Ovarian Malignancy (ROMA) - Determining the
Likelihood of Malignancy in Women with Pelvic Mass. European Medical
Journal - Gynecology and Obstetrics, 2012:1:40-43
58. Terlikowska et al. Preoperative HE4, CA-125 and ROMA in the
differential diagnosis of benign and malignant adnexal masses. Journal
of Ovarian Research (2016) 9:43
59. Claudia Valentina Georgescu et al. Value of immunochemistry in
confirming undifferentiated ovarian carcinomas. Morphol – Embryol.
2004. p.133–142
60. Kaspar HG, Crum CP. The Utility of Immunohistochemistry in the
Differential Diagnosis of Gynecologic Disorders. Arch Pathol Lab Med.
2015;139:39–54
61. Chen VW, Ruiz B, Killeen JL, Cote´TR, Wu XC, Correa CN. Pathology
and Classification of Ovarian Tumors North American Association of
Central Cancer Registries. The American Cancer Society Cancer
Supplement Volume 97 Number 10. 2003
62. Scully R, Sobin L. Histological typing of ovarian tumours, volume 9. New
York: Springer Berlin, 1999.
Universitas Sumatera Utara
63. Parmley, T, Benign Neoplasms of the Ovary, Fallopian Tube, and
Parovarian Region. Glob. libr. women's med., 2008
64. Edelman GM: Topobiology. New York, Basic Books, 1988
65. Parmley TH: Embryology of the female genital canal. In Kurman RJ (ed):
Blaustein's Pathology of the Female Genital Tract, 3rd ed. New York.
Springer-Verlag, 1987
66. Karst AM, Drapkin R. Review Article Ovarian Cancer Pathogenesis: A
Model in Evolution. Hindawi Publishing Corporation Journal of Oncology
Volume 2010, Article ID 932371, 13 pages doi:10.1155/2010/932371
67. Nezhat FR, Apostol R, Nezhat C, Pejovic T. New insights in the
pathophysiology of ovarian cancer and implications for screening and
prevention. American Journal of Obstetrics & Gynecology. September
2015. p262-267
68. Kurman RJ, Shih LM. The Origin and Pathogenesis of Epithelial Ovarian
Cancer- a Proposed Unifying Theory. Am J Surg Pathol. 2010 March ;
34(3): 433–443. doi:10.1097/PAS.0b013e3181cf3d79.
69. Montz FJ, Schlaerth JB, Morrow CP: The natural history of theca lutein
cysts. Obstet Gynecol 72: 247, 1988
70. Forrester K, Almoguera C, Han K et al: Detection of high incidence of Kras oncogenes during human colon tumorigenesis. Nature 327: 298,
1987
71. Nogales F: Germ cell tumors of the ovary. In Fox H (ed): Haines and
Taylor Obstetrical and Gynecological Pathology, p 637. New York,
Churchill Livingstone, 1987
72. Schummer M, Ng WV, Bumgarner RE, et al. Comparative hybridization
of an array of 21,500 ovarian cDNAs for the discovery of genes
overexpressed in ovarian carcinomas. Gene 1999;238:375–85.
73. Ono K, Tanaka T, Tsunoda T, et al. Identification by cDNA microarray of
genes involved in ovarian carcinogenesis. Cancer Res 2000;60:5007–11.
74. Welsh JB, Zarrinkar PP, Sapinoso LM, et al. Analysis of gene expression
profiles in normal and neoplastic ovarian tissue samples identifies
candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad
Sci U S A 2001;98:1176–81.
75. Schaner ME, Ross DT, Ciaravino G, et al. Gene expression patterns in
ovarian carcinomas. Mol Biol Cell 2003;14:4376–86.
Universitas Sumatera Utara
76. Hough CD, Sherman-Baust CA, Pizer ES, et al. Largescale serial
analysis of gene expression reveals genes differentially expressed in
ovarian cancer. Cancer Res 2000;60:6281–7.
77. Tapper J, Kettunen E, El-Rifai W, Seppala M, Andersson LC, Knuutila S.
Changes in gene expression during progression of ovarian carcinoma.
Cancer Genet Cytogenet 2001;128:1–6.
78. Wang K, Gan L, Jeffery E, et al. Monitoring gene expression profile
changes in ovarian carcinomas using cDNA microarray. Gene
1999;229:101–8.
79. Clauss A, Lilja H, Lundwall A. A locus on human chromosome 20
contains several genes expressing protease inhibitor domains with
homology to whey acidic protein. Biochem J 2002;368:233–242.
80. Bingle L, Singleton V, Bingle CD. The putative ovarian tumour marker
gene HE4 (WFDC2), is expressed in normal tissues and undergoes
complex alternative splicing to yield multiple protein isoforms. Oncogene
(2002) 21, p2768-73
81. Galgano MT et al. Comprehensive analysis of HE4 expression in normal
and malignant human tissues. Modern Pathology (2006) 19, 847–853
82. Bouchard D, Morisset D, Bourbonnais Y, Tremblay GM. Proteins with
whey-acidic-protein motifs and cancer. Lancet Oncol 2006; 7: 167–74
83. Berry NB, Cho YM, Harrington MA, et al. Transcriptional targeting in
ovarian cancer cells using the human epididymis protein 4 promoter.
Gynecologic Oncol 2004;92:896–904.
84. Devoogdt N, Revets H, Ghassabeh GH, et al. Secretory leukocyte
protease inhibitor in cancer development
85. Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2)
protein is a biomarker for ovarian carcinoma. Cancer Res 2003;63:3695–
700.
86. Escudero JM. Comparison of Serum Human Epididymis Protein 4 with
Cancer Antigen 125 as a Tumor Marker in Patients with Malignant and
Nonmalignant Diseases. Clinical Chemistry 57:11. 1534–1544 (2011)
87. Molina R, Navarro J, Filella X, Castel T, Ballesta AM. S-100 protein
serum levels in patients with benign and malignant diseases: falsepositive results related to liver and renal function. Tumour Biol
2002;23:39–44.
88. Notoadmojo S. Metodologi Penelitian Kesehatan. Penerbit PT Rineka
Karya. 2002
Universitas Sumatera Utara
89. Qureshi A, Pervez S. Allred scoring for ER reporting and its impact in
clearly distinguishing ER negative from ER positive breast cancers.
Journal Pakistan Medical Association, 60(5), (2010). p350-353
90. Georgakopoulos P, Mehmood S, Akalin A, Shroyer KR,
Immunohistochemical Localization of HE4 in Benign, Borderline, and
Malignant Lesions of the Ovary. Int J Gynecol Pathol Vol. 31, No. 6,
November 2012
Universitas Sumatera Utara
1. Frequently Asked Question FAQ075 Gynecologic Problem. The
American College of Obstetricians and Gynecologists. July 2015
2. Grabosch SM, Karjane NW. Ovarian Cysts. January 2017. Available at:
http://emedicine.medscape.com/article/255865-overview
3. Kaloo PD et al. Management of Suspected Ovarian Masses in
Premenopausal Women. Royal College of Obstetricians and
Gynaecologists Green-top Guideline No. 62. November 2011.p1-14
4. Modesitt SC, Pavlik EJ, Ueland FR, et al. Risk of malignancy in unicolar
ovarian cystic tumors less than 10 centimeters in diameter. Obstet
Gynecol. 2003; 102:594-599
5. Dorum A, Blom GP, Ekerhovd E, et al. Prevalence and histologic
diagnosis of adnexal cysts in postmenopausal women: an autopsy study.
Am J Obstet Gynecol. 2005; 192:48-54
6. Myers ER, Bastian LA, Havrilesky LJ, et al. Management of adnexal
mass. Evid Rep Technol Assess, 2006; 130:1-145
7. Knudsen UB, Tabor A, Mosgaard B, et al. Management of ovarian cysts.
Acta Obstet Gynecol Scand. 2004;83:1012-1021
8. Royal College of Obstetricians and Gynecologists. Ovarian cysts in
postmenopauseal women. October 2003. http://www.rcog.org.uk
9. National Cancer Institute. SEER cancer statistics review, 1975-2003.
http://seer.cancer.gov
10. Grabosch SM, Karjane NW. Ovarian Cysts. Jan 2017. Available at:
http://emedicine.medscape.com/article/255865-overview
11. Kim KA, et al. Benign Ovarian Tumors with Solid and Cystic Components
That Mimic Malignancy. American Journal of Roentgenology.
2004 182:5, 1259-1265
12. Hamed et al. Diagnostic Pathology 2013, 8:11. Available at :
http://www.diagnosticpathology.org/content/8/1/11
13. Karlsen NS, Karlsen MA, Høgdall CK, Høgdall EVS. HE4 Tissue
Expression and Serum HE4 Levels in Healthy Individuals and Patients
with Benign or Malignant Tumors: A Systematic Review. Cancer
Epidemiol Biomarkers Prev; 23(11) November 2014
Universitas Sumatera Utara
14. Zhu L et al. Overexpression of HE4 (human epididymis protein 4)
enhances proliferation, invasion and metastasis of ovarian cancer.
Oncotarget,
Vol.
7,
No.
1.
2015.
Available
at:
www.impactjournals.com/oncotarget/
15. Jinping Li. HE4 (WFDC2) Promotes Tumor Growth in Endometrial
Cancer Cell Lines. Int. J. Mol. Sci. 2013, 14, 6026-6043;
doi:10.3390/ijms14036026
16. Zhuang H, Gao J, Hu Z, Liu J, Liu D, et al. (2013) Co-Expression of
Lewis y Antigen with Human epididymis protein 4 in Ovarian Epithelial
Carcinoma. PLoS ONE 8(7): e68994. doi:10.1371/journal.pone.0068994
17. Moore, R.G. et al. HE4 (WFDC2) gene overexpression promotes ovarian
tumor growth. Sci. Rep. 4, 3574 (2014).
18. Drapkin R. Human epididymis protein 4 (HE4) Is a Secreted Glycoprotein
that Is Overexpressed by Serous and Endometrioid Ovarian Carcinomas.
Cancer Res 2005; 65: (6). March 15, 2005
19. Mayo clinic staff. Ovarian cyst. Available at: www.mayoclinic.org
20. Nordqvist C. Ovarian Cysts: Causes, Symptoms and Treatments. 2015.
Available at: http://www.medicalnewstoday.com
21. Suryati, Gambaran kejadian kista ovarium pada wanita usia Di rumah
sakit khusus daerah ibu dan anak Pertiwi makassar tahun 2014,
Universitas Indonesia Timur, Makassar, 2015
22. Safitri, Y., Pengalaman Wanita Usia Subur Dengan Kista Ovarium,
Departemen Epidemiologi, Fakultas Kesehatan Masyarakat, Universitas
Sumatera Utara, 2010.
23. Siringo D., Hiswani, Jemadi, Karakteristik penderita kista ovarium yang
dirawat inap di Rumah Sakit St Elizabeth Medan tahun 2008-2012,
Departemen Epidemiologi, Fakultas Kesehatan Masyarakat-Universitas
Sumatera Utara, 2012.
24. Parazzini F, Moroni S, Negri E, La Vecchia C, Dal Pino D, Ricci E. Risk
factors for functional ovarian cysts. Epidemiology. 1996 Sep;7(5):547-9.
25. Wiknjosastro, H. Tumor jinak pada alat genital, dalam Ilmu Kandungan,
Yayasan Bina Pustaka Sarwono Prawirohardjo, Jakarta, 2005, Hal :
355-62
26. Mansjoer, dkk., Kapita Selekta Kedokteran edisi ketiga jilid 1, Media
Aesculapius, Jakarta, 2000
Universitas Sumatera Utara
27. Choi, J.-H., Ovarian Epithelial Cancer: Etiology and Pathogenesis.
BioWave, vol. 10. 2008
28. Llewellyn, dkk., Dasar-dasar Obstetri dan Ginekologi, Hipokrates, ,
Jakarta, 2001
29. Auersperg, N., Wong, A. S. T., Choi, K.-C., Kang, S. K. & Leung, P. C. K,
Ovarian surface epithelium, in biology, endocrinology, and pathology.
Endocrine Reviews, volume 22, 2001, page: 255-88.
30. Denny L et al. Staging classification and clinical practice guidelines for
gynaecologic cancers. FIGO Committee on Gynecologic Oncology,
2009.
31. Brohet RM, Goldgar DE, Easton DF, et al. Oral contraceptives and
breast cancer risk in the international BRCA1/2 carrier cohort study: a
report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS
collaborating group. J Clin Oncol.2007;25:3831-6
32. WHO, GLOBOCAN, International agency of research and cancer 2008
33. Bustam M., Epidemiologi Penyakit Tidak Menular, Penerbit Rineka Cipta,
Jakarta, 2007.
34. du Bois A, Rochon J, Pfisterer J, Hoskins WJ. Variations in institutional
infrastructure, physician specialization and experience, and outcome in
ovarian cancer: a systematic review. Gynecol Oncol.2009;112:422-36.
35. Manuaba,I.B.C., & Manuaba, I.B.G., Buku Ajar Penuntun Kuliah
Ginekologi, Penerbit CV. Trans Ino Media, Jakarta, 2010
36. William H., C..2007. American College of Obstetricians and
Gynecologists Ovarian Cysts. http://emedicine.com diakses tanggal 24
Januari 2017
37. Robboy's, Pathology of The Female Reproductive Tract, Elsevier, 2009
38. Stanford JL. Oral contraceptives and
Contraception. 1991 Jun;43(6):543-56.
neoplasia
of
the
ovary.
39. Vessey M, Metcalfe A, Wells C, McPherson K, Westhoff C, Yeates D.
Ovarian neoplasms, functional ovarian cysts, and oral contraceptives. Br
Med J (Clin Res Ed). 1987 Jun 13;294(6586):1518-20.
Universitas Sumatera Utara
40. Henderson,C., Kista Ovarium, dalam Buku Ajar Konsep Kebidanan,
EGC, Jakarta, 2005
41. Rostgaard K. Does pregnancy induce the shedding of premalignat
ovarian cells? Epidemiology.2003;14:168
42. Whittermore AS. Characteristic relating to ovarian cancer risk,
Collaborating ovarian cancer group. Am J Epidemiol.1992;136:11841203
43. Kumar, V., Abbas, A.K., Fausto, N. & Aster, J.C., Robbins & Cotran,
Ovarian Cyst, in Pathologic Basis of Diseases. 2010
44. Kurman RJ, Shih le-Ming. Pathogenesis of ovarian cancer: lessons from
morphology and molecular biology and their clinical implications. Int J
Gynecol Pathol. 2008;27(2):151-60
45. Barber HR, Graber EA. The PMPO syndrome (postmenopausal palpable
ovary syndrome). Obstet Gynecol 1971;38:921–3.
46. Kahraman K, Ozguven I, Gungor M, Atabekoglu CS. Extremely elevated
serum CA-125 level as a result of unruptured unilateral endometrioma:
the highest value reported. Fertil Steril 2007;88:15–7.
47. Van Calster B, Timmerman D, Bourne T, Testa AC, Van Holsbeke C,
Domali E, et al. Discrimination between benign and malignant adnexal
masses by specialist ultrasound examination versus serum CA-125. J
Natl Cancer Inst 2007;99:1706–14.
48. McLemore MR, Aouizerat BE, Lee KA, Chen LM, Cooper B, Tozzi M. A
comparison of the cyclic variation in serum levels of CA-125 across the
menstrual cycle using two commercial assays. Biol Res Nurs
2012;14:250–6.
49. Hamed EO, Ahmed H, Sedeek OB, Mohammed AM, Abd-Alla AA, Abdel
Ghaffar HM. Significance of HE4 estimation in comparison with CA-125
in diagnosis of ovarian cancer and assessment of treatment response.
Diagn Pathol 2013;23:8–11.
50. Demir RH, Marchand GJ. Adnexal masses suspected to Be benign
treated with laparoscopy. JSLS 2012;16:71–84.
51. Timmerman D, Ameye L, Fischerova D, Epstein E,Melis GB, Guerriero
S, et al. Simple ultrasound rules to distinguish between benign and
malignant adnexal masses before surgery: prospective validation by
IOTA
group.
BMJ
2010;14(341):c6839.
http://dx.doi.org/10.1136/bmj.c6839.
Universitas Sumatera Utara
52. Cramer DW, Bast Jr RC, Berg CD, Diamandis EP, Godwin AK, Hartge P,
et al. Ovarian cancer biomarker performance in prostate, lung, colorectal,
and ovarian cancer screening trial specimens. Cancer Prev Res
2011;4:365–74.
53. Ferraro S, Braga F, Lanzoni M, Boracchi P, Biganzoli EM, Panteghini M.
Serum human epididymis protein 4 vs carbohydrate antigen 125 for
ovarian cancer diagnosis: a systematic review. Journal of clinical
pathology. 2013;66(4):273-81.
54. Hussain, F. Gynecologic Tumor Markers Overview [Internet]. Medscape;
1 August 2012, cited 19 November 2014. Available at:
http://emedicine.medscape.com/article/269839-overview#showall.
55. Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk
of malignancy index incorporating CA-125, ultrasound and menopausal
status for the accurate preoperative diagnosis of ovarian cancer. Br J
Obstet Gynecolo. 1990; 97:922-9
56. Granato T, Porpora MG, Longo F, Angeloni A, Manganaro L, Anastasi E.
HE4 in the differential diagnosis of ovarian masses. Clinica Chimica Acta
446 (2015) 147–155
57. Vucetic Z. Risk of Ovarian Malignancy (ROMA) - Determining the
Likelihood of Malignancy in Women with Pelvic Mass. European Medical
Journal - Gynecology and Obstetrics, 2012:1:40-43
58. Terlikowska et al. Preoperative HE4, CA-125 and ROMA in the
differential diagnosis of benign and malignant adnexal masses. Journal
of Ovarian Research (2016) 9:43
59. Claudia Valentina Georgescu et al. Value of immunochemistry in
confirming undifferentiated ovarian carcinomas. Morphol – Embryol.
2004. p.133–142
60. Kaspar HG, Crum CP. The Utility of Immunohistochemistry in the
Differential Diagnosis of Gynecologic Disorders. Arch Pathol Lab Med.
2015;139:39–54
61. Chen VW, Ruiz B, Killeen JL, Cote´TR, Wu XC, Correa CN. Pathology
and Classification of Ovarian Tumors North American Association of
Central Cancer Registries. The American Cancer Society Cancer
Supplement Volume 97 Number 10. 2003
62. Scully R, Sobin L. Histological typing of ovarian tumours, volume 9. New
York: Springer Berlin, 1999.
Universitas Sumatera Utara
63. Parmley, T, Benign Neoplasms of the Ovary, Fallopian Tube, and
Parovarian Region. Glob. libr. women's med., 2008
64. Edelman GM: Topobiology. New York, Basic Books, 1988
65. Parmley TH: Embryology of the female genital canal. In Kurman RJ (ed):
Blaustein's Pathology of the Female Genital Tract, 3rd ed. New York.
Springer-Verlag, 1987
66. Karst AM, Drapkin R. Review Article Ovarian Cancer Pathogenesis: A
Model in Evolution. Hindawi Publishing Corporation Journal of Oncology
Volume 2010, Article ID 932371, 13 pages doi:10.1155/2010/932371
67. Nezhat FR, Apostol R, Nezhat C, Pejovic T. New insights in the
pathophysiology of ovarian cancer and implications for screening and
prevention. American Journal of Obstetrics & Gynecology. September
2015. p262-267
68. Kurman RJ, Shih LM. The Origin and Pathogenesis of Epithelial Ovarian
Cancer- a Proposed Unifying Theory. Am J Surg Pathol. 2010 March ;
34(3): 433–443. doi:10.1097/PAS.0b013e3181cf3d79.
69. Montz FJ, Schlaerth JB, Morrow CP: The natural history of theca lutein
cysts. Obstet Gynecol 72: 247, 1988
70. Forrester K, Almoguera C, Han K et al: Detection of high incidence of Kras oncogenes during human colon tumorigenesis. Nature 327: 298,
1987
71. Nogales F: Germ cell tumors of the ovary. In Fox H (ed): Haines and
Taylor Obstetrical and Gynecological Pathology, p 637. New York,
Churchill Livingstone, 1987
72. Schummer M, Ng WV, Bumgarner RE, et al. Comparative hybridization
of an array of 21,500 ovarian cDNAs for the discovery of genes
overexpressed in ovarian carcinomas. Gene 1999;238:375–85.
73. Ono K, Tanaka T, Tsunoda T, et al. Identification by cDNA microarray of
genes involved in ovarian carcinogenesis. Cancer Res 2000;60:5007–11.
74. Welsh JB, Zarrinkar PP, Sapinoso LM, et al. Analysis of gene expression
profiles in normal and neoplastic ovarian tissue samples identifies
candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad
Sci U S A 2001;98:1176–81.
75. Schaner ME, Ross DT, Ciaravino G, et al. Gene expression patterns in
ovarian carcinomas. Mol Biol Cell 2003;14:4376–86.
Universitas Sumatera Utara
76. Hough CD, Sherman-Baust CA, Pizer ES, et al. Largescale serial
analysis of gene expression reveals genes differentially expressed in
ovarian cancer. Cancer Res 2000;60:6281–7.
77. Tapper J, Kettunen E, El-Rifai W, Seppala M, Andersson LC, Knuutila S.
Changes in gene expression during progression of ovarian carcinoma.
Cancer Genet Cytogenet 2001;128:1–6.
78. Wang K, Gan L, Jeffery E, et al. Monitoring gene expression profile
changes in ovarian carcinomas using cDNA microarray. Gene
1999;229:101–8.
79. Clauss A, Lilja H, Lundwall A. A locus on human chromosome 20
contains several genes expressing protease inhibitor domains with
homology to whey acidic protein. Biochem J 2002;368:233–242.
80. Bingle L, Singleton V, Bingle CD. The putative ovarian tumour marker
gene HE4 (WFDC2), is expressed in normal tissues and undergoes
complex alternative splicing to yield multiple protein isoforms. Oncogene
(2002) 21, p2768-73
81. Galgano MT et al. Comprehensive analysis of HE4 expression in normal
and malignant human tissues. Modern Pathology (2006) 19, 847–853
82. Bouchard D, Morisset D, Bourbonnais Y, Tremblay GM. Proteins with
whey-acidic-protein motifs and cancer. Lancet Oncol 2006; 7: 167–74
83. Berry NB, Cho YM, Harrington MA, et al. Transcriptional targeting in
ovarian cancer cells using the human epididymis protein 4 promoter.
Gynecologic Oncol 2004;92:896–904.
84. Devoogdt N, Revets H, Ghassabeh GH, et al. Secretory leukocyte
protease inhibitor in cancer development
85. Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2)
protein is a biomarker for ovarian carcinoma. Cancer Res 2003;63:3695–
700.
86. Escudero JM. Comparison of Serum Human Epididymis Protein 4 with
Cancer Antigen 125 as a Tumor Marker in Patients with Malignant and
Nonmalignant Diseases. Clinical Chemistry 57:11. 1534–1544 (2011)
87. Molina R, Navarro J, Filella X, Castel T, Ballesta AM. S-100 protein
serum levels in patients with benign and malignant diseases: falsepositive results related to liver and renal function. Tumour Biol
2002;23:39–44.
88. Notoadmojo S. Metodologi Penelitian Kesehatan. Penerbit PT Rineka
Karya. 2002
Universitas Sumatera Utara
89. Qureshi A, Pervez S. Allred scoring for ER reporting and its impact in
clearly distinguishing ER negative from ER positive breast cancers.
Journal Pakistan Medical Association, 60(5), (2010). p350-353
90. Georgakopoulos P, Mehmood S, Akalin A, Shroyer KR,
Immunohistochemical Localization of HE4 in Benign, Borderline, and
Malignant Lesions of the Ovary. Int J Gynecol Pathol Vol. 31, No. 6,
November 2012
Universitas Sumatera Utara